Tendinopathy - Pipeline Insight, 2024

This “Tendinopathy - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Tendinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tendinopathy: Understanding

Tendinopathy: Overview

Tendinopathy is a common musculoskeletal condition characterized by pain, impaired function, and structural changes within the tendon. It is a complex disorder that can affect tendons throughout the body, with the most commonly affected sites being the Achilles, patellar, and rotator cuff tendons. Tendinopathy is often associated with overuse, repetitive strain, or acute injury, but can also occur without a clear inciting event. The pathogenesis involves a maladaptive response to tendon loading, leading to a breakdown of the normal tendon structure and function. Accurate diagnosis and targeted management are crucial, as tendinopathy can significantly impact an individual's physical activity, quality of life, and ability to perform daily tasks.

Tendinopathy, characterized by pain, swelling, and reduced function, presents a spectrum of symptoms that can vary depending on the affected tendon and the severity of the condition. Common signs include localized burning pain, tenderness, and swelling around the tendon, worsened during and after activity, stiffness in the joint, restricted movement, and persistent pain lasting for several months. Patients may also experience a grating sensation as the tendon moves, weakness in the affected area, and a lump on the tendon. These symptoms can impact daily activities and sports performance, often leading individuals to seek medical attention for diagnosis and treatment. Understanding these signs and symptoms is crucial for timely intervention and effective management of tendinopathy to prevent further complications and promote recovery.

The treatment and management of tendinopathy involves a multi-faceted approach, with eccentric exercises being the most consistently effective intervention across systematic reviews. Eccentric exercises, which involve lengthening the muscle-tendon unit under load, are recommended as first-line treatment, with daily sessions for at least 12 weeks. If tendinopathy is refractory to eccentric exercises, extracorporeal shockwave therapy (ESWT) can be considered as a second-line option, as it has demonstrated effectiveness similar to eccentric strengthening. These two approaches can also be combined for better outcomes. For patients who do not respond to eccentric exercises and ESWT, high-volume injections of normal saline, corticosteroids, or anesthetics may be beneficial in reducing pain and improving long-term function, particularly in Achilles or patellar tendinopathy. Surgical management is typically reserved as a last resort when conservative interventions have failed. Other adjunct treatments, such as splints, orthotics, taping, and dry needling, may provide additional benefits when used in combination with the primary interventions.

"Tendinopathy - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tendinopathy pipeline landscape is provided which includes the disease overview and Tendinopathy treatment guidelines. The assessment part of the report embraces, in depth Tendinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tendinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tendinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Tendinopathy.

Tendinopathy Emerging Drugs Chapters

This segment of the Tendinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tendinopathy Emerging Drugs

TenoMiR: Causeway Therapeutics

TenoMiR (CWT-001), a microRNA replacement therapy which directly targets critical disease pathways restoring tendons to normal structure and function. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Tendinopathy.

Tendinopathy: Therapeutic Assessment

This segment of the report provides insights about the different Tendinopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tendinopathy

There are approx. 5+ key companies which are developing the therapies for Tendinopathy. The companies which have their Tendinopathy drug candidates in the most advanced stage, i.e. Phase II include, Causeway Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tendinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tendinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tendinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tendinopathy drugs.

Tendinopathy Report Insights

• Tendinopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tendinopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tendinopathy drugs?
• How many Tendinopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tendinopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tendinopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tendinopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MiMedx
• Causeway Therapeutics
• Deciphera Pharmaceuticals

Key Products

• dHACM
• TenoMiR
• Vimseltinib

This product will be delivered within 2 business days.